References
- Fidel PL, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996; 9: 335–348.
- Nyirjesy P. Chronic vulvovaginal candidiasis. Am Fam Phys 2001; 63: 697–702.
- Crislip MA, Edwards JE. Candida albicans and related species. In: Gorbach, Bartlett, Blacklow, eds. Infectious Diseases, Philadelphia, Saunders, 1992: 1887–1895.
- Sobel JD. Vulvovaginitis. In Hoeprich, Colin, Jordan, Ronald, eds. Infectious Diseases, 5th edn, Philadelphia, Lippincott Company, 1994: 575-582.
- Ringdahl EN. Treatment of recurrent vulvovaginal can-didiasis. Am Fam Phys 2000; 61: 3306–3312.
- Haefner HK. Current evaluation and management of vulvovaginitis. Clin Obstet Gynecol 1999; 42: 184–195.
- Altman PM. Australian tea tree oil. Aust J Pharma 1988; 69: 276–278.
- Hammer KA, Carson CF, Riley TV. Influence of organic matter, cations and surfactants on the antimicrobial activity of Melaleuca alternifolia (tea tree) oil in vitro. J Appl Microbiol 1999; 86: 446–452.
- May J, Chan CH, King A, Williams L, French GL. Time-kill studies of tea tree oil on clinical isolates. J Antimicrob Chemother 2000; 45: 639–643.
- Cox SD, Mann CM, Markham JL, et al. The mode of antimicrobial action of the essential oil of Melaleuca alternifo-lia (tea tree oil). J Appl Microbiol 2000; 88: 170–175.
- Mann CM, Cox SD, Markham JL. The outer mem-brane of Pseudomonas aeruginosa NCTC 6749 contributes to its tolerance to the essential oil of Melaleuca alternifolia tea tree oil. Lett Appl Microbiol 2000; 30: 294–297.
- Pena EF. Melaleuca alternifolia oil. Obstet Gynecol 1962; 19: 793–795.
- Hammer KA, Carson CF, Riley TV. In vitro activity of essential oils, in particular Melaleuca alternifolia (tea tree) oil and tea tree oil products, against Candida spp. J Antimicrob Chemother 1998; 42: 591–595.
- Larone DH. Medically Important Fungi — A Guide to Identification, 3rd edn. Washington, DC, ASM Press, 1995.
- National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. NCCLS, Wayne, PA, 1997.
- Meis J, Petrou M, Bille J, et al. A global evaluation of the susceptibility of Candida species to fluconazole by disk dif-fusion. Diagn Microbiol Infect Dis 2000; 36: 215–223.
- Lee SC, Fung CP, Lee N, et al. Fluconazole disk diffu-sion test with methylene blue-and glucose-enriched Mueller-Hinton agar for determining susceptibility of Candida species. J Clin Microbiol 2001; 39: 1615–1617.
- Nenoff P, Haustein UF, Brandt W. Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol 1996; 9: 388–394.
- Beylier MF. Bacteriostatic activity of some Australian essential oils. Perfum Flavor 1979; 4: 23–25.
- Christoph F, Kaulfers PM, Stahl-Biskup E. A compara-tive study of the in vitro antimicrobial activity of tea tree oils s.l. with special reference to the activity of I3-triketones. Planta Med 2000; 66: 556-560.
- Banes-Marshall L, Cawley P, Phillips CA. In vitro activi-ty of Melaleuca alternifolia (tea tree) oil against bacterial and Candida spp. isolates from clinical specimens. Br J Biomed Sci 2001; 58: 139–145.
- D'Auria FD, Laino L, Strippoli V, et al. In vitro activity of tea tree oil against Candida albicans mycelial conversion and other pathogenic fungi. J Chemother 2001; 13 (4): 377–383.
- Carson CF, Riley TV. The antimicrobial activity of tea tree oil. Med J Aust 1994; 160:236.
- Kirkpatrick WR, Turner TM, Fothergill AW, et al. Fluconazole disk diffusion susceptibility testing of Candida species. J Clin Microbiol 1998; 36: 3429–3432.